Welcome to our dedicated page for LB PHARMACEUTICALS SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB PHARMACEUTICALS INC director Ran Nussbaum received a new stock option grant. He was awarded options for 10,000 shares of common stock at an exercise price of $27.95 per share, expiring on June 2, 2036.
All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this compensation grant, he holds 10,000 stock options directly, with no open‑market buying or selling reported in this filing.
LB Pharmaceuticals Inc director Rebecca Luse received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. All underlying shares vest on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, as long as she remains in continuous service.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options covering 12,500 shares of common stock. The options carry an exercise price of $27.95 per share and expire on June 2, 2036, functioning as equity-based compensation rather than an open-market trade.
Footnotes explain that 2,500 of these options represent a prorated annual grant for a prior year under the company’s non-employee director compensation policy. All 12,500 underlying shares vest 100% on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, contingent on Mr. Lenz’s continuous service.
LB Pharmaceuticals director Rekha Hemrajani received a new stock option grant tied to the company’s common stock. The award covers 10,000 shares with an exercise price of $27.95 per share and expires on June 2, 2036.
These options were granted as compensation and not purchased on the open market. All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, if she remains in continuous service through that date. Following this grant, she holds 10,000 stock options directly.
LB Pharmaceuticals Inc director granted stock options as part of equity compensation. Director William P. Kane Jr received options for 10,000 shares of common stock, giving him the right to buy those shares at an exercise price of $27.95 per share until June 2, 2036.
According to the filing, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, if he continues to serve through that date. After this grant, he holds options for 10,000 shares directly.
LB Pharmaceuticals Inc. director Garland J. Scott received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. This is a compensation-related award, not an open-market purchase or sale.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, subject to Scott’s continuous service through the vesting date. Following the grant, Scott holds 10,000 stock options directly.
LB Pharmaceuticals Inc. Amendment No. 1 to a Schedule 13G/A reports that TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and Chen Yu collectively disclose beneficial ownership of 1,839,489 shares of Common Stock, representing 6.4% of the class based on 28,674,827 shares outstanding as of March 23, 2026.
The filing states these shares are held of record by TCG Crossover II; voting and dispositive power is shared through the general partner and Chen Yu as sole managing member. This Amendment supplements an Original Schedule 13G filed September 18, 2025.
LB PHARMACEUTICALS INC ownership disclosure: Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson and Michael Kramarz report beneficial ownership of 1,972,369 shares of Common Stock as of March 31, 2026, including 1,500,000 shares held and 472,369 shares issuable upon exercise of a Pre-Funded Warrant. Ownership percentages use 28,674,827 shares outstanding as of March 31, 2026 reported in the issuer's Form 10-Q filed May 12, 2026. The Pre-Funded Warrant is subject to a Beneficial Ownership Limitation of 9.99%.
LB Pharmaceuticals Inc reports that Caligan Partners LP and David Johnson hold 1,438,070 shares of Common Stock, representing 5.0% of the class. The filing states the ownership percentage is based on 28,674,827 shares outstanding as of March 23, 2026.
The cover data shows the Reporting Persons have shared voting power and shared dispositive power over the 1,438,070 shares. The statement is signed by David Johnson on May 15, 2026 and cites the company address as 575 Madison Avenue, New York, NY.
JPMorgan Chase & Co. filed an amendment to a Schedule 13G/A reporting beneficial ownership of 1,427,568 shares of LB Pharmaceuticals Inc. Common Stock, representing 4.9% of the class as reported.
The filing shows sole voting power over 1,311,423 shares and sole dispositive power over 1,427,568 shares. The reported filing cites affiliated entities including JPMorgan Chase Bank, N.A. and J.P. Morgan Investment Management Inc. The amendment is signed by a Vice President on 05/13/2026.